RxDoctor Payments Data

Krystal Schmieg

Family · West Burlington, IANPI 1427774074

Payments from drug & device makers

$1,208in general payments, 2019–2025

Across 30 payments — averaging $40.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$404
  • AstraZeneca$272
  • Verona Pharma, Inc.$124
  • Sanofi-aventis U.S. LLC$100
  • Boehringer Ingelheim$81
  • Sanofi$53
  • plus $176 from 5 others

What the payments were for

  • Food & beverage$94078%
  • Education$26822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$36,444
Medicare patients
179
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$124,938
Breztri AerosphereBudesonide/Glycopyr/Formoterol109$71,632
NucalaMepolizumab12$44,496
Breo ElliptaFluticasone/Vilanterol77$33,278
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$27,039
SymbicortBudesonide/Formoterol Fumarate77$22,007
Advair HfaFluticasone Propion/Salmeterol53$19,320
Spiriva RespimatTiotropium Bromide22$17,247
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$16,822
Fluticasone-SalmeterolFluticasone Propion/Salmeterol98$9,119
Albuterol Sulfate HfaAlbuterol Sulfate301$7,539
Arnuity ElliptaFluticasone Furoate21$5,736
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$4,981
Ventolin HfaAlbuterol Sulfate80$4,286
DuleraMometasone/Formoterol11$4,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$35$235,488317 claims
AstraZenecaBreztri Aerosphere, Symbicort$272$93,638186 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$81$34,06955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in West Burlington

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →